Published in Cancer Weekly, October 16th, 2001
Antisoma has acquired exclusive worldwide rights to use of the enzyme, recombinant cytotoxic RNase, in combination with monoclonal antibodies that target PEM (polymorphic epithelial mucin) and CEA (carcinoembryonic antigen) - protein...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.